PDCD1 and Hodgkins lymphoma: Immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) inhibitors, have an established role in the clinical management of relapsed and refractory systemic HL, raising the possibility of their utility in CNS‐HL.28